Ron Zwanziger (born 1954) is an American businessman.[1] He is best known for founding and leading the diagnostic test manufacturer Alere.
Early life and education
editZwanziger was born in Israel in 1954 and raised on the island of Cyprus after 1956.[2][3]
He earned an engineering degree from Imperial College London in 1975 and an MBA from Harvard Business School in 1981.[4][2]
Career
editMedisense (1981-1991)
editAlong with three business school classmates, Zwanziger co-founded Medisense Inc., a maker of glucose meters used in diabetes home care, in 1981.[3][5][2] He was CEO until 1991.[2]
Originally, the company worked on 13 disparate biotechnology ideas, hoping one or another would pay off.[3] By 1984, the company had narrowed its focus to one of the projects, which concerned electrochemical biosensors.[a][3]
In 1987, Medisense introduced the ExacTech, which was the first electrochemical biosensor-based glucose meter for home use.[6] This technology required less blood to obtain a reading, and by 2008 was used in a majority of the 6 billion home blood glucose tests being performed annually.[6] In his textbook on electrochemistry, Alan Bond of Monash University suggests that the commercial success of electrochemical home glucose monitoring "predominantly can be attributed to the introduction of the ExacTech system."[7]
Medisense was acquired by Abbott Laboratories in 1996 for $876 million.[8]
Alere (1991-2014)
editZwanziger founded Alere Inc. (then called Selfcare Inc.),[9][4] a diagnostic test manufacturer, in 1991.[2] He was CEO until 2014.[10][11][12]
Alere's diabetes unit was sold to Johnson and Johnson (LifeScan) in 2001 for $1.3 billion.[13][9] With the 2001 acquisition of the subsidiary Unipath from Unilever, Alere became the leading manufacturer of ovulation and pregnancy tests.[3] Alere acquired Biosite Inc. in a $1.7 billion hostile takeover in 2007.[14] By 2012, Alere was the largest manufacturer in the HIV testing space, according to the nonprofit Population Services International.[15]
Abbott acquired Alere in 2017 for $5.3 billion.[16][9]
LumiraDx (2014-2023)
editAlong with longtime partners[3] Drs. David Scott and Jerry McAleer, Zwanziger co-founded the diagnostic test manufacturer LumiraDx in 2014.[17] He was CEO until November 2023, when all three founders resigned amid "financial difficulties" at the company.[18] On December 29, 2023, LumiraDx reached a $350 million agreement to sell its key assets to Roche Diagnostics.[19]
LumiraDx produces several rapid diagnostic tests which are read by a single brick-sized device at the point of care. A 2021 presentation by Bill Gates hailed the LumiraDx platform as "amazing" and "cheaper and smaller than the diagnostic devices that came before."[20] A 2021 meta-analysis of 133 studies showed that LumiraDx's COVID-19 rapid antigen test had the highest sensitivity among 61 products.[21]
References
edit- ^ 2 of the other projects (which concerned Dutch elm disease and metabolic engineering) had been sold or spun off, and the rest scrapped.
- ^ Douglas, Craig M. (11 August 2008). "Boston's barbarian?". Boston Business Journal. Retrieved 28 December 2017.
Sign In Required
- ^ a b c d e Pederson, Jay; Grant, Tina (2004). "Inverness Medical Innovations, Inc". International Directory of Company Histories. St. James Press. Retrieved 5 June 2020.
- ^ a b c d e f Isenberg, Daniel (2006). Inverness Medical Innovations--Born Global (A). Harvard Business School Publishing.
- ^ a b "Ron Zwanziger: Executive Profile & Biography". Bloomberg. May 11, 2001. Retrieved December 28, 2017.
- ^ Worthless, Impossible and Stupid: How Contrarian Entrepreneurs Create and Capture Extraordinary Value. Harvard Business Review Press. 2013. p. 25. ISBN 978-1-4221-8699-2. Retrieved December 28, 2017.
- ^ a b Heller, Adam; Feldman, Ben (2008). "Electrochemical Glucose Sensors and Their Applications in Diabetes Management". Chemical Reviews. 108 (7): 2482–2505. doi:10.1021/cr068069y. PMID 18465900.
- ^ Bond, Alan (2002). Broadening Electrochemical Horizons: Principles and Illustration of Voltammetric and Related Techniques. Oxford University Press.
- ^ "Abbott Laboratories to Buy Medisense for $876 Million". The New York Times. 30 March 1996. Retrieved 28 December 2017.
- ^ a b c Cyran, Robert (January 1, 2016). "Strategy of Alere Board Paid Off With Buyout by Abbott". The New York Times. Retrieved December 28, 2017.
- ^ "Alere chief executive Ron Zwanziger resigns, effective immediately - The Boston Globe". bostonglobe.com. Retrieved 28 December 2017.
- ^ "Alere Inc. CEO Zwanziger, Other Top Executives Resign In Overhaul". BioSpace. July 2, 2014. Retrieved December 28, 2017.
- ^ "Alere's' Ex-CEO plans $3.82 billion offer for health company". www.ohio.com. December 28, 2017. Retrieved December 28, 2017.
- ^ "J&J acquires Inverness unit - May 23, 2001". money.cnn.com. Retrieved 28 December 2017.
- ^ "Inverness wins Biosite with bid of $1.68 billion". sandiegouniontribune.com. Retrieved 1 January 2018.
- ^ "Actress, Activist and PSI Ambassador Debra Messing and HRH Crown Princess Mette-Marit of Norway Present 2012 Impact Awards". PRWeb. Population Services International. 26 July 2012. Retrieved 4 July 2020.[dead link]
- ^ Ignorance, Out of (27 October 2017). "Abbott's Inviting New Allure". seekingalpha.com. Retrieved 28 December 2017.
- ^ "Who We Are". LumiraDx. Retrieved 12 May 2020.
- ^ "QuotedData's morning briefing 2 November 2023". QuotedData. 2 November 2023. Retrieved 21 November 2023.
- ^ Mirasol, Feliza (4 January 2024). "Roche to Acquire Point-of-Care Technology from LumiraDx in $350 Million Deal". BioPharm International. Retrieved 22 January 2024.
- ^ Gates, Bill. "New tools for COVID testing". YouTube. Retrieved 22 January 2024.
- ^ Brümmer, Lukas E.; Katzenschlager, Stephan; Gaeddert, Mary; Erdmann, Christian; Schmitz, Stephani; Bota, Marc; Grilli, Maurizio; Larmann, Jan; Weigand, Markus A.; Pollock, Nira R.; Macé, Aurélien; Carmona, Sergio; Ongarello, Stefano; Sacks, Jilian A.; Denkinger, Claudia M. (12 August 2021). "Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: A living systematic review and meta-analysis". PLOS Medicine. 18 (8): e1003735. doi:10.1371/journal.pmed.1003735. ISSN 1549-1676. PMC 8389849. PMID 34383750.